Skip to main content
All lobbying filings

TARPLIN, DOWNS & YOUNG, LLC

Lobbying for AMYLYX PHARMACEUTICALS · Company dedicated to the development of potential therapies for neurodegenerative diseases

 Filing 1st Quarter - Report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Income
$40,000.00
What the client paid this registrant for the period.
Client based in
Massachusetts

Official filing document

 Lobbyists on this filing 6
  • JENNIFER B YOUNG
    Previously held: Asst. Sec. for Leg.- HHS; Dep. Asst. Sec for Leg. - HHS; Cmte. Staff, House Cmte. on Ways and Means; Cmte. Staff. Sen. Cmte. on Finance
  • RAISSA H DOWNS
    Previously held: Prin. Dep. Asst. Sec for Leg.-HHS; Dep. Asst. Sec. for Leg.-HSS; Staff Dir., Sub Cmte. on Employment, Sen. HELP Cmte.
  • PAMELA SMITH
    Previously held: Leg. Dir., Sen. Tom Harkin; Dep. Staff Dir., Sen. HELP Cmte.; Staff Dir., Sen. HELP Cmte.; Counsel to Asst. AG, Civil Div., Dept. of Justice; Spec. Counsel, Ofc of Leg. Affairs, Dept. of Justice; Counsel and LA, Sen. Carol Moseley-Braun
  • MARGARET JOSEPH
    Previously held: CoS for Sen. Kyrsten Sinema, CoS for Rep. Kyrsten Sinema, CoS for Rep. Bobby Bright, CoS for Rep. Jim Matheson, Clerk for House Rules Cmte.
  • PETER FISE
    Previously held: Health Counsel for Sen. Cmte on Finance, Health Counsel for Sen. Jeanne Shaheen, Staff Assistant for House Cmte on Oversight & Government Reform
  • PARICK BRAERTON CARROLL
    Previously held: Leg Asst. Rep. Ray LaHood, Leg Dir. Rep. Kevin Yoder, PSM Senate Appropriations Cmte.

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Lobbying activity 2
Health Issues

rare disease and access to innovation

Medicare/Medicaid

rare disease and access to innovation

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem